Skip to main content

Posts

Showing posts from September, 2023

BLUNT TRAUMA TO EYE VARIOUS FINDINGS

Blunt trauma to the eye can result in a wide range of findings and injuries, depending on the force and direction of the impact. The Trauma can be due to Direct Injury Contre-coup Injury Shearing forces and shock waves. The eye is a delicate organ with several components, and trauma can result into open or closed globe injuries. Following are some of the findings and injuries commonly associated with blunt trauma to different components of the eye:         Eyelids and Surrounding Tissues: ü   Contusions and bruising of the eyelids and periorbital area. May give an appearance of Raccoon Eyes. ü   Lacerations or cuts on the eyelids. ü   Swelling and edema of the eyelids.         Conjunctiva: ü   Subconjunctival hemorrhage, which appears as redness on the white part of the eye. ü   Chemosis, which is swelling of the conjunctiva.         Cornea: ü   Corneal abrasions or scratches, causing pain, redness, and foreign body sensation. ü   Corneal edema, which can r

MOPETT Trial (Multicenter Observational Study of Pulmonary Embolism Thrombolysis)-2013

  MOPETT trial (Multicenter Observational Study of Pulmonary Embolism Thrombolysis)  was a randomized controlled trial that evaluated the efficacy and safety of low-dose thrombolysis in patients with acute intermediate-risk pulmonary embolism (PE).  The trial included 121 patients who were randomly assigned to receive either low-dose alteplase (50 mg) or low-dose heparin plus placebo.  The primary endpoint of the trial was the development of pulmonary hypertension at 28 months. The secondary endpoints were recurrent PE at 28 months and major bleeding events.  The results of the trial showed that  l ow-dose alteplase significantly reduced the risk of developing pulmonary hypertension at 28 months compared to low-dose heparin plus placebo (28% vs. 56%) . There was no significant difference between the two groups in the risk of recurrent PE or major bleeding events.  The MOPETT trial provides evidence that low-dose thrombolysis is an effective and safe treatment option for patie